| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T435 |
0-230 |
Sentence |
denotes |
Conversely, Cao et al. (313) conducted a controlled open‐label study with 199 hospitalized severe COVID‐19 patients randomly divided into two groups: a standard care group and a lopinavir/ritonavir treatment group (400 mg/100 mg). |
| T436 |
231-417 |
Sentence |
denotes |
No benefit was observed in the lopinavir/ritonavir treatment group, showing no significant results for faster clinical improvement, lower mortality, or decreased viral RNA detectability. |
| T437 |
418-624 |
Sentence |
denotes |
Although there are 85 clinical trials in progress testing lopinavir/ritonavir associated with other drugs on SARS-CoV-2 and/or COVID-19, WHO stopped the study of lopinavir/ritonavir in the Solidarity Trial. |
